Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer

BACKGROUND: This study was designed to evaluate toxicity and preliminary efficacy of 2 cycles of concomitant standard dose/schedule of (153)Sm-lexidronam plus Q 3 weeks schedule escalating doses of docetaxel in metastatic castration-resistant prostate cancer (mCRPC). METHODS: mCRPC patients with pro...

詳細記述

保存先:
書誌詳細
主要な著者: Lin, Jianqing, Sinibaldi, Victoria J., Carducci, Michael A., Denmeade, Samuel, Song, Danny, DeWeese, Theodore, Eisenberger, Mario A.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483074/
https://ncbi.nlm.nih.gov/pubmed/19962920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2009.10.003
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料